文献速递神经核医学

在轻度认知障碍中引入淀粉样蛋白状态评估的门控系统

Introducing a gatekeeping system for amyloid status assessment in mild cognitive impairment.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-07-14

研究基于342例轻度认知障碍患者的APOE基因型、18F-FDG PET、年龄和性别,训练机器学习分类器预测淀粉样蛋白状态,并在两个数据集上测试;预测的淀粉样蛋白状态与金标准状态对进展为痴呆的风险指示作用至少相当。作者认为该算法能较好近似淀粉样蛋白状态,有助于基于已有生物标志物信息估计进展为阿尔茨海默病的个体风险,并支持筛选最可能从进一步病因学检查中获益的患者。

要点

  • 在APOE-ε4非携带者中预测淀粉样蛋白阴性、在携带者中预测淀粉样蛋白阳性的精度为87%,召回率分别为79%和51%。
  • 预测的淀粉样蛋白状态与金标准状态对进展为痴呆风险的指示作用至少相当。
  • 算法利用APOE基因型、18F-FDG PET、年龄和性别信息近似轻度认知障碍患者的淀粉样蛋白状态,可靠性良好。

核心结论

  • 作者开发了利用APOE基因型、18F-FDG PET、年龄和性别信息在轻度认知障碍中近似淀粉样蛋白状态的算法,可靠性良好。
  • 作者认为该算法可基于已有生物标志物信息更好地估计进展为阿尔茨海默病的个体风险,并支持高效筛选最可能从进一步病因学检查中获益的患者。
  • 作者讨论了该算法在临床常规和临床试验中的进一步潜在用途。

研究设计与样本

  • 研究纳入342例轻度认知障碍患者,训练不同机器学习分类器,基于18F-FDG PET、年龄和性别预测APOE-ε4非携带者和携带者中的淀粉样蛋白状态多数类。
  • APOE-ε4非携带者的多数类为淀粉样蛋白阴性,APOE-ε4携带者的多数类为淀粉样蛋白阳性。
  • 分类器在两个不同数据集上测试,并比较金标准与预测淀粉样蛋白状态下的进展为痴呆频率。

主要发现

  • APOE-ε4非携带者中淀粉样蛋白阴性、APOE-ε4携带者中淀粉样蛋白阳性的预测精度为87%,召回率分别为79%和51%。
  • 预测的淀粉样蛋白状态与金标准淀粉样蛋白状态对进展为痴呆的风险指示作用至少相当。

关键数值与推荐

  • APOE-ε4非携带者中淀粉样蛋白阴性预测的精度为87%、召回率为79%。
  • APOE-ε4携带者中淀粉样蛋白阳性预测的精度为87%、召回率为51%。

临床怎么用

  • 作者认为该算法可基于已有生物标志物信息估计进展为阿尔茨海默病的个体风险。
  • 作者认为该算法可支持高效筛选最可能从进一步病因学检查中获益的患者。
  • 作者讨论了该算法在临床常规和临床试验中的进一步潜在用途。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with mild cognitive impairment (MCI), enhanced cerebral amyloid-β plaque burden is a high-risk factor to develop dementia with Alzheimer's disease (AD). Not all patients have immediate access to the assessment of amyloid status (A-status) via gold standard methods. It may therefore be of interest to find suitable biomarkers to preselect patients benefitting most from additional workup of the A-status. In this study, we propose a machine learning-based gatekeeping system for the prediction of A-status on the grounds of pre-existing information on APOE-genotype 18F-FDG PET, age, and sex. METHODS: Three hundred and forty-two MCI patients were used to train different machine learning classifiers to predict A-status majority classes among APOE-ε4 non-carriers (APOE4-nc; majority class: amyloid negative (Aβ-)) and carriers (APOE4-c; majority class: amyloid positive (Aβ +)) from 18F-FDG-PET, age, and sex. Classifiers were tested on two different datasets. Finally, frequencies of progression to dementia were compared between gold standard and predicted A-status. RESULTS: Aβ- in APOE4-nc and Aβ + in APOE4-c were predicted with a precision of 87% and a recall of 79% and 51%, respectively. Predicted A-status and gold standard A-status were at least equally indicative of risk of progression to dementia. CONCLUSION: We developed an algorithm allowing approximation of A-status in MCI with good reliability using APOE-genotype, 18F-FDG PET, age, and sex information. The algorithm could enable better estimation of individual risk for developing AD based on existing biomarker information, and support efficient selection of patients who would benefit most from further etiological clarification. Further potential utility in clinical routine and clinical trials is discussed.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Doering E, Hoenig MC, Bischof GN, et al. Introducing a gatekeeping system for amyloid status assessment in mild cognitive impairment. Eur J Nucl Med Mol Imaging. 2022. PMID: 35831715. doi:10.1007/s00259-022-05879-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。